Jia Chen

Executive Director, Head of Clinical Pharmacology and Project leader @ Abogen Biosciences

About

-Expertise in clinical pharmacology (especially using allometric scaling, IVIVE and modelling methods to estimate the starting dose for phase I study and optimize the dose selection for phase II study of the new drug) and pharmacometrics (especially for oncologic products) with hands-on experience of NONMEM, WINNONLIN, NLME, R, Simcyp, ADAPT5 and Berkeley Madonna. -Translational Oncology drug development experience globally from discovery to PoC/PoM, as well as late phase drug development in China for NMPA NDA approval -Experience in using PK/PD modelling and simulation approach to draft appropriate drug-specific BE guidance on generic drug development, especially for PD or clinical endpoint based BE study, as well as provided scientific consults on PK/PD or statistical related issues.

Country

China

City

Shanghai

Industry

Pharmaceuticals

Skill

Clinical pharmacokinetics, Pharmacometrics, Pharmacogenetics

Experience

Executive Director, Head of Clinical Pharmacology and Project leader

Abogen Biosciences

2026-2 - Present · 8 mos

Head of Clinical Pharmacology

Simcere Zaiming

2023-3 - 2026-2 · 3 yrs

中国上海市

Director, clinical pharmacology

先声药业 Simcere

2022-3 - 2023-3 · 1 yr 1 mo

中国上海市

Sr manager, Clinical Pharmacology and pharmacometrics

Johnson & Johnson Innovative Medicine

2021-4 - 2022-2 · 11 mos

中国上海市

Support global and local program/study to set up the ClinPharm strategy; Act as hematology ClinPharm TA lead in China to align with global hematology TA strategy

Investigator, Oncology Clinical Pharmacology

Novartis

2017-8 - 2021-4 · 3 yrs 9 mos

Shanghai

Support global Oncology study from preclinical to PoC; Support China submission from clinical pharmacology perspective; Join the initiative of generic drug quality consistency evaluation